“We assessed multiple biomarkers from low quality and quantity samples. [Ion Torrent Genexus System] also allowed flexible sample batch sizes…with a total turnaround of less than 18 hours from DNA to data.”

Hear more from Dr. Hewitt in this free, on demand presentation from OncomineWorld, a virtual NGS education meeting.

“With the GeneStudio S5 system, our lab has a turnaround time of less than five working days, and with the introduction of the Genexus sequencer, the turnaround time was further reduced to three days. We can even provide…molecular profiling in less than 24 hours for some urgent cases…We receive excellent support from the company…to facilitate NGS testing from initial training to ordering, from machine service and maintenance to volumatic pipeline development and implementations. Thermo Fisher always have experts in place to support every step of the workflow…”

“On the sequencer side, this is basically a self-contained laboratory that includes not just a gene sequencer, but also library preparation and bioinformatic analysis on a single instrument. The panel itself, the Oncomine Precision Assay, is novel…in that it also looks at circulating cell-free tumor derived RNA to detect fusions as opposed to the most of the commercially available assays, which are looking only at DNA.”

“All of the fusions present in our samples were detected by Oncomine Precision Assay and there were 5 unique fusions [detected by Oncomine Precision Assay] which were not previously covered by the reference standard.”

Hear more from Dr. Grafodatskaya in her recent presentation at OncomineWorld, a virtual NGS education meeting

“Oncomine Solutions came as a great differential for our laboratory because we were the pioneers in using this solution in Brazil. Before, to research EGFR, it was necessary to use real-time PCR…using a smaller amount of material. Often the material is scarcer - with PCR alone it was not enough to prepare the slide. Oncomine Solutions allow you to investigate several genes and different types of point mutations, gene fusions, and amplifications…faster and more precisely using a minimal amount of material.”

“[Oncomine Comprehensive Assay Plus] may introduce decentralized HRD testing in any lab using Thermo Fisher NGS…This platform can be used for a variety of complex biomarker assessments like tumor mutational burden, microsatellite instability, LOH, or the genomic instability metric.”

Hear more from Dr. Staebler in the OncomineWorld 2023 presentation entitled, “Oncomine Comprehensive Assay Plus – Genomic Instability Metric (GIM)

“We wanted to significantly reduce our turnaround time without compromising quality...and staffing and available expertise was also a big consideration…The Ion Torrent Genexus [System] is unique in that it automates the sample-to-report workflow within a day.”

Hear more in our free and on demand webinar series on the Ion Torrent Genexus System

“[With the Oncomine Precision Assay on the Genexus System], simultaneous DNA and RNA analysis allow us to reduce the amount of sample used for analysis, reduce the number of incomplete analyses for insufficient material, easily conduct data analysis…and reduce the days of analysis from the sample arriving to result, altogether resulting in more accurate results.”

Hear more from Dr. Destro in the OncomineWorld 2023 presentation entitled, “Simultaneous DNA and RNA variant testing by Oncomine Precision Assay”

“The Genexus System with its automated processing offers an advantage over other NGS systems by reducing turnaround times as well as operating costs.”

Read more about LABOPAT’s implementation of the Oncomine Precision Assay on the Ion Torrent Genexus System in a recent issue of Genexus System News.

“The Genexus System has demonstratable prowess in performing automated NGS and will become a leader in oncology clinical research testing, an area where expectations, in terms of testing speed, comprehensiveness, and cost, are rapidly rising.”

Read more about Dr. Chan’s study in a recent issue of Genexus System News.

“We value the Oncomine Precision Assay so much; it is an efficient way to use a small sample. We try to use samples with at least 20 percent tumor cells, but we do occasionally have to go as low as 5 percent – and, even when that happens, 98 percent of samples yield a conclusive result.”

Read more in Dr. Navarro’s interview in a recent issue of Genexus System News.

“OCAPlus gives us the possibility to analyze mutations, fusions, CNVs, and loss of heterozygosity for more than 500 genes. In addition, we get multiple biomarker profiling, providing us information on mutational signature, calculation of TMB, and assessment of MSI status. We only use as little as 20ng of DNA or RNA for the assay…There is a high rate of successful sequencing with the assay and the bioinformatics pipeline allows fast turnaround time of results.”

Hear more from Dr. Raineri and other users on the Oncomine Comprehensive Assay Plus in this free, on-demand webinar on comprehensive genomic profiling.

“Two years ago, we moved our workflows to the Genexus™ system. From our point of view, it combines the Ion Chef and S5 platforms into a single unit so we can enter the genetic material on the front end and obtain sequencing results on the back end. It creates a more automated and streamlined workflow and will create a significant reduction in turnaround time as well as hands-on time for the technologist.”

Read more from Dr. Seidman and other users in this recent article about the Ion Torrent Genexus System (article attached entitled Torrent of Praise)

“We value the key advantages of the Genexus platform:  speed, accuracy, and a high degree of sophisticated automation. Together, these minimize man-hours while reducing turnaround times to as little as two days.”

Read more from Dr. Ballester and other users in this recent article about the Ion Torrent Genexus System (article attached entitled Torrent of Praise).

“By doing NGS on the Ion Torrent Genexus System, we ended up consolidating all of our single-gene tests. No need for 10 different QCs, check lists, all the different proficiencies…It benefits the laboratory overall and provides cost savings.”

Hear more from Dr. Vail in this presentation from a recent virtual event.

“The amplicon-based NGS genomic profiling enables around a 96% success rate with DNA and with RNA a 98% success rate in our hands, which for us is a success story…”

Hear more from Dr. Hofman in this free, on-demand webinar on the Oncomine Dx Express Test 

“The Oncomine Myeloid GX v2 Assay covers the vast majority of important myeloid genes. It demonstrated promising accuracy and reproducibility and achieved a 3% LOD."

Learn more from Dr. Krigstein in this Unlocking Blood Cancer Insights with NGS Webinar

“Oncomine Comprehensive Assay Plus delivers high sequencing success rates capable of providing results to >95% of samples and this all-in-one assay is highly automatable for in-house comprehensive genomic profiling (CGP)."

See more in this recent webinar from The Pathologist